申请人:Merck Sharp & Dohme Ltd.
公开号:US05985896A1
公开(公告)日:1999-11-16
The present invention provides compounds of formula (I), wherein R.sup.1 is phenyl or a 5- or 6-membered aromatic heterocyclic group containing 1, 2, 3 or 4 heteroatoms, selected from nitrogen, oxygen and sulphur, which aryl or heteroaryl group is optionally substituted; R.sup.2 is hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, CF.sub.3, OCF.sub.3, NO.sub.2, CN, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, CO.sub.2 R.sup.a, CONR.sup.a R.sup.b, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl or C.sub.1-4 alkyl substituted by C.sub.1-4 alkoxy, where R.sup.a and R.sup.b each independently represent hydrogen or C.sub.1-4 alkyl; R.sup.4, R.sup.5, R.sup.6, R.sup.9a and R.sup.9b, A, X, and Y are as defined in the specification; the dotted line is an optional double bond; Q.sup.1 is oxygen, sulphur or --NH--; Q.sup.2 is --N.dbd., --NH--, --CH.dbd. or --CH.sub.2 --; and m is zero or 1; and pharmaceutically acceptable salts and prodrugs thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia. ##STR1##
本发明提供了公式(I)的化合物,其中R.sup.1是苯基或含有1、2、3或4个杂原子(氮、氧和硫)的5-或6元芳香杂环基,该芳基或杂芳基可以选择性地被取代;R.sup.2是氢、卤素、C.sub.1-6烷基、C.sub.1-6烷氧基、CF.sub.3、OCF.sub.3、NO.sub.2、CN、SR.sup.a、SOR.sup.a、SO.sub.2R.sup.a、CO.sub.2R.sup.a、CONR.sup.aR.sup.b、C.sub.2-6烯基、C.sub.2-6炔基或C.sub.1-4烷基,所述C.sub.1-4烷基被C.sub.1-4烷氧基取代,其中R.sup.a和R.sup.b各自独立地表示氢或C.sub.1-4烷基;R.sup.4、R.sup.5、R.sup.6、R.sup.9a和R.sup.9b、A、X和Y如规范中所定义;虚线是可选的双键;Q.sup.1是氧、硫或--NH--;Q.sup.2是--N.dbd.、--NH--、--CH.dbd.或--CH.sub.2--;m为零或1;以及其药学上可接受的盐和前药。这些化合物特别适用于治疗或预防疼痛、炎症、偏头痛、恶心和后遗神经痛。##STR1##